Comparing Coherus BioSciences (CHRS) & Its Competitors
Coherus BioSciences (NASDAQ: CHRS) is one of 288 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Coherus BioSciences to similar businesses based on the strength of its analyst recommendations, earnings, valuation, dividends, risk, institutional ownership and profitability.
Earnings & Valuation
This table compares Coherus BioSciences and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Coherus BioSciences||$165.24 million||-$111.05 million||-4.87|
|Coherus BioSciences Competitors||$464.94 million||$167.77 million||-6.75|
Coherus BioSciences’ peers have higher revenue and earnings than Coherus BioSciences. Coherus BioSciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent recommendations and price targets for Coherus BioSciences and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Coherus BioSciences Competitors||1380||4480||12320||312||2.63|
Coherus BioSciences presently has a consensus price target of $34.78, suggesting a potential upside of 168.55%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.20%. Given Coherus BioSciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Coherus BioSciences is more favorable than its peers.
Volatility & Risk
Coherus BioSciences has a beta of 4.32, indicating that its stock price is 332% more volatile than the S&P 500. Comparatively, Coherus BioSciences’ peers have a beta of 6.57, indicating that their average stock price is 557% more volatile than the S&P 500.
This table compares Coherus BioSciences and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Coherus BioSciences Competitors||-4,766.74%||-354.83%||-43.39%|
Institutional & Insider Ownership
78.2% of Coherus BioSciences shares are held by institutional investors. Comparatively, 51.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 26.3% of Coherus BioSciences shares are held by company insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Coherus BioSciences beats its peers on 7 of the 12 factors compared.
Coherus BioSciences Company Profile
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company’s product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.
Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.